Sphera Funds Management’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Sphera Funds Management’s Portfolio GNMX Stock Details GNMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-405,000	Closed	-$753K	–	147
2017 Q1	$753K	Sell	405,000 -45,000	-10%	-$204K	0.15%	97
2016 Q4	$2.33M	Hold	450,000	–	–	0.59%	50
2016 Q3	$2.51M	Hold	450,000	–	–	0.41%	63
2016 Q2	$2.5M	Buy	+450,000	New	+$2.36M	0.65%	48
2015 Q2	–	Sell	-175,000	Closed	-$1.41M	–	170
2015 Q1	$1.41M	Sell	175,000 -50,000	-22%	-$377K	0.15%	124
2014 Q4	$1.14M	Buy	+225,000	New	+$1.11M	0.19%	106

Other funds holding GNMX

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

ECM

Element Capital Management New York $3.2B AUM 29.54% 1-Year Est. Return

Sphera Funds Management's GNMX Position: Q2 2017 in Review

Sphera Funds Management sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2017, closing a stake of 405,000 shares — an estimated $753K sold.

Sphera Funds Management first reported a position in GNMX in Q4 2014 and held it in 6 quarters. The position peaked at $2.51M in Q3 2016. 51 funds tracked by Wall St. Rank hold GNMX as of Q2 2017.

Sphera Funds Management reported no remaining Aevi Genomic Medicine Inc position as of Q2 2017 after selling out during the quarter.
Sphera Funds Management sold 405,000 Aevi Genomic Medicine Inc shares in Q2 2017, an estimated $753K.
Sphera Funds Management first reported a position in Aevi Genomic Medicine Inc in Q4 2014 and held it in 6 quarters.
Sphera Funds Management's Aevi Genomic Medicine Inc position peaked at $2.51M in Q3 2016.
51 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2017.

Based on Sphera Funds Management's 13F filing for Q2 2017, filed 9 Aug 2017.